People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Pharmaceuticals, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Promedior Inc | — | Pharmaceuticals | Series B | $46.3M | $739.9M | 2009 |
| Zikani Therapeutics, Inc. | — | Pharmaceuticals | Series A | $31.7M | $232.3M | 2018 |
| Zelos Therapeutics Inc | — | Pharmaceuticals | Series A | $17.8M | $75.0M | 2009 |
| SiteOne Therapeutics, Inc. | — | Pharmaceuticals | Series A | $16.1M | $460.3M | 2015 |
| Thrasos Innovation Inc. | — | Biotechnology | Series A | $14.0M | $506.1M | 2015 |
| Xcellerex, Inc. | — | Other | Seed | $2.0M | $36.4M | 2011 |
Joseph Zakrzewski at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joseph Zakrzewski on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Amir Nashat | 1 | 14 |
| Jens Eckstein | 1 | 8 |
| Lawrence Miller | 1 | 8 |
| Jean George | 1 | 6 |
| JOSEPH S. ZAKRZEWSKI | 1 | 6 |
| Vikas Goyal | 1 | 5 |
| Colin Goddard | 1 | 5 |
| Raj Parekh | 1 | 5 |
| Farah Champsi | 1 | 5 |
| James W. Broderick | 1 | 5 |
| Rick Orr | 1 | 5 |
| Harold R. Werner | 1 | 4 |
| Lowell E. Sears | 1 | 4 |
| Markus Goebel | 1 | 4 |
| Andrew Myers | 1 | 4 |
| Henry Skinner | 1 | 4 |
| Will Price | 1 | 4 |
| Brian MacDonald | 1 | 4 |
| Donald Hayden | 1 | 3 |
| John H. Friedman | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.